Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer.

Prostate Int · 2025 · PMC11979369 · PMID 40213348

Europe PMC DOI

hedged sentence

0.1345

closest p · 2.7× alpha

0.1345

boldest claim

The sentences

difference was apparentP =0.1345not close (p > 0.1)

Of note, no significant difference was apparent between patients with low-volume + cT4 and high-volume+≤cT3 ( P =0.1345).

also in 195 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.